Nanotechnology Tools for Infection Control: Scanning New Horizons on Next-Generation Therapies to Eradicate Pathogens and Fight Drug Resistance

by Alessandro Poma (Editor), Loris Rizzello (Editor)

Overview

Nanotechnology Tools for Infections Control: Scanning New Horizons on Next-Generation Therapies to Eradicate Pathogens and Fight Drug Resistance provides an overview of recent strategies to build nanotechnology platforms, with a specific focus on biocompatible and biodegradable nanosystems. Particular attention is given to responsive nanoparticles, which are able to sense and respond to specific external stimuli (e.g., temperature, pH). The book includes details of the rationale behind the design of the raw materials, synthetic procedures and characterization techniques. It also introduces a new generation of nanomaterials, commonly named as 'nanobots', which are able to self-propel in response to external stimuli. Subsequent sections of the book focus on the applications of nanosystems as an alternative approach to standard antibiotics. The chapters describe their pharmokinetic and dynamics within the body, their ability to cross biological barriers and how they distribute within different body compartments. In this respect, a dedicated section highlights the crucial role of the immune system, as well as of protein corona, in changing the nanoparticles retention within the body. Coverage is also given to describe how nanosystems access different cells and their intracellular trafficking. - Provides an overview of the current challenges in infection and immunity, showing how nanosystems can be used to meet them - Focuses on the translational potential of nanotechnology for both clinical and commercial applications - Assesses the major challenges of effectively using nanotechnology in immunology

Product Details

ISBN-13:	9780128239957
Publisher:	Elsevier Science
Publication date:	08/26/2024
Series:	Micro and Nano Technologies
Sold by:	Barnes & Noble
Format:	eBook
Pages:	300
File size:	17 MB
Note:	This product may take a few minutes to download.

About the Author

Alessandro Poma received his MSc in Pharmaceutical Technology and Chemistry from the University of Palermo (Italy) in 2009. He then joined the Cranfield Biotechnology Group led by Prof. Sergey Piletsky to undertake a PhD in Biosensors and Nanomaterials (Cranfield University, 2013). He moved to UCL in 2014, first as an NC3Rs David Sainsbury Fellow and subsequently in other roles, and he has been appointed Lecturer in Biomaterials and Allied Subjects in the Division of Biomaterials and Tissue Engineering in 2019. His key research area is the development of molecularly imprinted nanomaterials as synthetic antibodies, and their polymeric biodegradable composites for diagnostic, therapeutic and tissue engineering applications
Loris Rizzello received his MSc (Magna cum Laude) in Biotechnology at the University of Salento (Italy) in 2008, and the PhD in nanoscience at the Italian institute of Technology (IIT) in 2012. He then joined the University College London (UCL), Department of Chemistry, as International Newton Postdoctoral Fellow (by The Royal Society) under the supervision of Prof. Giuseppe Battaglia. He moved to the Institute for Bioengineering of Catalonia (IBEC) of Barcelona as a Marie Curie Fellow in 2018. He has been appointed as Associate Professor of Protein Engineering and ERC-StG grantee at the University of Milan, Department of Pharmaceutical Science, since October 2020. From March 2021, he is also Junior Group Leader at National Institute of Molecular Genetics of Milan (INGM), where he leads the Infection Dynamics Laboratory. His key research area is the use of cell-derived biomimetic nanoparticles for the treatment of intracellular pathogens infections, with a focus on the eradication of human tuberculosis. He also investigates the innate and adaptive immune response to Mycobacteria infections.

Table of Contents

1. Introduction2. The significant drain in antimicrobial discovery by pharma companies3. Design and production of nanoparticles4. Nanoparticles characterisation and standardisation5. Navigating the nanoscale: principles of body navigation6. Intracellular fate of nanosystems, their degradation and body accumulation7. Molecular targets and pharmacodynamics for bactericidal and bacteriostatic activity8. How to fight bacteria without inducing drug resistance9. Pre-clinical characterisation: which animal model is best for infection?10. Clinical translation and envisioned impact of nanotech for infection control: economy, government policy and public awareness

What People are Saying About This

From the Publisher

A focused overview of nanotechnology-inspired therapies being used to create more effective antibiotics